Drostanolone Propionate Raw Powder is a high-purity steroidal raw material also known as Dromostanolone Propionate and Masteron Propionate. AAS Raw Pharma supplies white or almost white crystalline powder with a stated minimum assay of 99.7% for qualified laboratory research, analytical testing, method development, reference work, and legally authorised pharmaceutical manufacturing.
Each commercial enquiry can be assessed according to the required quantity, destination, documentation, packaging format, and intended lawful application. Batch-specific quality records may be requested before purchase, subject to availability.
Important notice: This product is a bulk chemical raw material. It is not a finished medicine, sterile injectable preparation, dietary supplement, or consumer product, and it is not intended for direct human or veterinary use. Drostanolone Propionate is controlled or otherwise regulated in many jurisdictions. The buyer is responsible for confirming that purchase, possession, importation, transport, storage, processing, and use are lawful.
Drostanolone Propionate Raw Powder is the propionate ester of drostanolone, also called dromostanolone. Drostanolone is a synthetic steroidal compound structurally related to dihydrotestosterone. Esterification with propionic acid produces a chemically distinct substance with its own molecular formula, molecular weight, CAS number, and analytical profile.
The compound is widely recognised under the name Masteron. Other names appearing in scientific databases, historical records, and commercial catalogues include Dromostanolone Propionate, Drolban, Masterid, Masteril, Prometholon, and 17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3-one propionate.
AAS Raw Pharma supplies the substance strictly as a raw material for qualified professional customers. The powder has not been formulated into a finished product and must not be interpreted as ready for injection, ingestion, personal use, or therapeutic administration.
| Specification | Product information |
|---|---|
| Product name | Drostanolone Propionate Raw Powder |
| Alternative name | Dromostanolone Propionate |
| Common market name | Masteron, Masteron Propionate |
| Chemical name | 17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3-one propionate |
| CAS number | 521-12-0 |
| EINECS number | 208-303-1 |
| UNII | X20UZ57G4O |
| Molecular formula | C23H36O3 |
| Molecular weight | 360.53 g/mol |
| Stated purity | 99.7% minimum, subject to batch documentation |
| Appearance | White or almost white crystalline powder |
| Physical form | Crystalline solid |
| Listed grade | Pharmaceutical raw-material grade |
| Storage | Sealed, protected from light, and stored according to batch documentation |
| Packaging | Sealed foil bag, rigid protective container, or approved bulk packaging |
| Documentation | Batch-specific COA and technical documents where available |
| Intended users | Qualified laboratories, institutions, and authorised manufacturers |
| Direct human use | Not permitted; this is not a finished product |
The CAS number, molecular formula, and molecular weight are independently supported by the FDA’s substance record, NIST Chemistry WebBook, and recognised analytical-reference suppliers.
Specifications published on the website are general commercial information. Final product acceptance should be based on the corresponding batch label, Certificate of Analysis, purchase specification, and the customer’s independent quality procedures.
Drostanolone Propionate Raw Powder is identified by CAS 521-12-0 and the formula C23H36O3. Its molecular weight is approximately 360.53 g/mol. The FDA’s substance database lists Dromostanolone Propionate as the preferred substance name and identifies 17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3-one propionate as a recognised chemical name.
These identifiers are important because informal names such as Masteron can be ambiguous in purchasing records. A professional quotation, purchase order, shipping document, or receiving record should identify the product by its full chemical name and CAS number.
The substance is an esterified steroidal compound rather than a formulated medicine. Its chemical identity does not establish that a particular commercial batch meets any pharmacopeial, manufacturing, purity, sterility, or regulatory standard. Those characteristics must be established separately through documentation and testing.
Buyers may encounter this material under several alternative names:
The NIST Chemistry WebBook records several of these historical and chemical synonyms.
For procurement purposes, Drostanolone Propionate Raw Powder, CAS 521-12-0 is the clearest description. Using both the full name and CAS number reduces the risk of confusion with Drostanolone Enanthate, unesterified drostanolone, or unrelated steroidal raw materials.
AAS Raw Pharma describes the product as a white or almost white crystalline powder. An established analytical-reference supplier similarly identifies Drostanolone Propionate as a crystalline solid.
Appearance can be useful during receiving inspection, but it cannot by itself confirm identity, purity, assay, authenticity, or suitability. Many unrelated chemical materials may have a similar colour and physical form.
Professional customers should compare the product label and batch number with the accompanying documentation and perform appropriate incoming-material testing where required by their quality system.
The AAS Raw Pharma specification lists a minimum purity of 99.7%, subject to confirmation in the documentation for the batch supplied. Purity should not be assessed from appearance, supplier reputation, or a generic website claim alone.
A meaningful assay statement depends on several factors:
Customers requiring a particular assay should request the current batch COA before completing an order. Independent confirmation may also be appropriate depending on the intended application and the receiving organisation’s procedures.
A Certificate of Analysis, commonly abbreviated as COA, is a batch-specific quality document. Depending on the specification and tests performed, a COA for Drostanolone Propionate raw material may include:
An analytical-reference supplier’s published COA demonstrates the value of reporting individual identity and quality tests rather than relying only on a headline purity percentage. Its example includes infrared identification, mass spectrometry, nuclear magnetic resonance, melting-point, rotation, and purity results. Those results apply to that supplier’s specific lot and must not be represented as results for AAS Raw Pharma material.
Customers should verify that the lot number on any AAS Raw Pharma COA matches the product packaging. A COA belonging to another supplier or batch cannot substantiate the quality of the material offered here.
A comprehensive raw-material evaluation can involve more than assay testing. Depending on the agreed specification and intended professional application, quality control may examine:
The presence or absence of a particular test must be confirmed from the actual batch documentation. AAS Raw Pharma should not claim HPLC, GC-MS, NMR, heavy-metal, residual-solvent, sterility, microbiological, or pharmacopeial testing unless that test appears in the relevant quality records.
Customers operating under formal quality systems should establish their own approved supplier, sampling, quarantine, testing, release, deviation, and record-retention procedures.
The phrase pharmaceutical grade is frequently used by raw-material suppliers, but it should be supported by a defined and verifiable specification. It does not automatically mean that the powder complies with USP, BP, EP, IP, GMP, FDA, MHRA, or another regulatory framework.
A product described as meeting an enterprise or in-house standard has been evaluated against the supplier’s own specification. Customers should request that specification and compare it with their technical, regulatory, and manufacturing requirements.
Avoid making any of the following claims unless documentary evidence is available:
Using precise, supportable language increases credibility and reduces the risk of misleading customers or search engines.
Drostanolone Propionate and Drostanolone Enanthate share the drostanolone parent structure, but they contain different ester groups. They are separate chemical substances with different identifiers and molecular characteristics.
| Feature | Drostanolone Propionate | Drostanolone Enanthate |
|---|---|---|
| Parent structure | Drostanolone | Drostanolone |
| Ester group | Propionate | Enanthate |
| Common abbreviation | Masteron P | Masteron E |
| CAS number | 521-12-0 | 13425-31-5 |
| Molecular formula | C23H36O3 | C27H44O3 |
| Molecular weight | 360.53 g/mol | Approximately 416.6 g/mol |
| Same raw material | No | No |
| Interchangeable | No | No |
A buyer requesting Masteron powder should specify which ester is required. The safest procurement description for this page is Drostanolone Propionate Raw Powder, CAS 521-12-0.
Drostanolone Propionate has appeared historically under names such as Masteron and Drolban. It was previously investigated and used in medical contexts, including historical treatment of certain breast cancers.
That history does not establish a current approved indication for the raw material offered by AAS Raw Pharma. Medical practices, product approvals, and legal classifications vary by country and change over time. A raw chemical ingredient must never be presented as an approved medicine merely because the compound has a history of pharmaceutical use.
This product page therefore does not make claims concerning cancer treatment, cholesterol reduction, hormonal therapy, athletic performance, fat loss, diuresis, or muscle development.
Subject to customer qualification and local law, Drostanolone Propionate raw powder may be relevant to professional work such as:
One analytical supplier describes Drostanolone Propionate raw powder as suitable for analytical method development, validation, and quality-control applications.
The availability of a raw material does not authorise any particular application. Each customer is responsible for determining whether its organisation, facility, personnel, and intended activity satisfy relevant laws and licence requirements.
Drostanolone Propionate Raw Powder is not ready for injection. A crystalline chemical ingredient is fundamentally different from a sterile, finished pharmaceutical product.
Manufacturing an injectable medicine requires controls that may include:
A purity result, even when high, does not demonstrate sterility, freedom from endotoxins, injectable suitability, clinical safety, or regulatory approval. AAS Raw Pharma does not provide home-manufacturing, conversion, brewing, filtration, injection, or self-administration instructions.
The supplied content recommends shaded, confined preservation. In clearer commercial language, this means keeping the material sealed, protected from light, and secured against unauthorised access.
Published reference products do not all use the same storage temperature. Cayman Chemical lists -20 degrees C for its analytical standard, while LGC listings for other reference-standard formats show refrigerated conditions such as +4 degrees C or +5 degrees C.
These differences illustrate why a customer should follow the label, stability information, and documentation supplied with the exact AAS Raw Pharma batch. General storage practices include:
Do not assign a shelf life or storage temperature unless it is supported by batch-specific or product-specific stability information.
Drostanolone Propionate Raw Powder is a biologically active and potentially regulated substance. It should be handled only by trained personnel in an appropriate professional environment.
A workplace risk assessment should address:
Drostanolone Propionate Raw Powder must not be tasted, swallowed, deliberately inhaled, injected, or applied directly to the body. Keep it away from children, unauthorised persons, household areas, food, beverages, and animal supplies.
If accidental exposure occurs, follow the facility’s emergency procedure and seek appropriate professional medical advice. The applicable Safety Data Sheet should be available to personnel before the package is opened.
AAS Raw Pharma can assess packaging requirements according to order quantity, destination, and approved use. Possible configurations may include:
Packaging should support identity, traceability, containment, and protection during normal transport and storage. A package label should identify the product, batch, quantity, and relevant handling information.
The final packaging method must comply with applicable carrier, export, import, and destination requirements. AAS Raw Pharma does not offer disguised, falsely declared, or deliberately mislabeled shipments.
Samples may be available to qualified laboratories, institutions, and authorised commercial buyers, subject to inventory, intended use, destination laws, and customer verification. Sample availability and charges should be confirmed before an order is placed.
For a sample or bulk quotation, customers should provide:
Larger or recurring requirements may be discussed separately. Availability, production capacity, lead time, minimum order quantity, and price should be confirmed in a formal quotation rather than assumed from general website copy.
AAS Raw Pharma supports qualified customers seeking documented steroidal raw materials for lawful professional applications.
The product has a stated minimum purity of 99.7%, subject to the analytical results and documentation for the supplied batch.
Direct commercial sourcing can support competitive quotations for approved orders. Final pricing depends on quantity, batch availability, testing, documentation, packaging, and destination.
Customers may request the available COA, SDS, specification, and other technical information for the current batch before purchase.
Sample, development, and bulk requirements may be assessed according to stock, customer qualification, and applicable regulations.
Packaging can be selected to protect the powder and maintain product and batch identification throughout lawful storage and transport.
AAS Raw Pharma can review delivery options for destinations where exportation, transportation, importation, possession, and intended use are permitted.
Support is available for product specifications, documentation, quotation terms, packaging, and shipment questions. Customers should report any discrepancy promptly with the relevant order and batch information.
To request a quotation for Drostanolone Propionate Raw Powder, provide complete and accurate purchasing details:
AAS Raw Pharma may request additional information before accepting an order. Submission of an enquiry does not guarantee product availability, shipment, customs clearance, or order approval.
International delivery may be considered where the shipment is lawful and accepted by the chosen carrier. Possible logistics providers may include DHL, FedEx, UPS, TNT, EMS, or an approved freight service, depending on route and product classification.
Carrier availability varies according to destination, quantity, documentation, and applicable transport restrictions. The mention of a carrier does not guarantee that it will accept every shipment.
The customer is responsible for verifying:
AAS Raw Pharma does not guarantee customs clearance and does not falsify labels, values, descriptions, invoices, or declarations to avoid inspection.
Drostanolone Propionate raw Powder is controlled in a number of jurisdictions. Cayman Chemical identifies it as a Schedule III compound in the United States and restricts its reference product to research and forensic applications.
Its classification in other countries may differ. Depending on location, purchasing or possessing the compound may require:
Customers must obtain independent legal and regulatory advice where necessary. A product listing does not represent confirmation that the substance may be bought, imported, or used in a particular jurisdiction.
This page provides technical and commercial information about a raw chemical ingredient. It is not medical advice and does not recommend Drostanolone Propionate raw powder for bodybuilding, cutting, muscle definition, athletic performance, strength retention, weight management, cancer treatment, or any personal purpose.
Dosage instructions such as 200-800 mg per week have intentionally been excluded. Such guidance is inappropriate for a bulk raw powder and could encourage unsafe or unlawful self-administration.
AAS Raw Pharma does not claim that this raw material diagnoses, treats, cures, or prevents any disease. Any legitimate treatment decision must involve a licensed healthcare professional and a lawfully authorised finished medicinal product.
Drostanolone Propionate Raw Powder is the crystalline raw form of the propionate ester of drostanolone. It is intended for qualified research, analytical, reference, and other lawfully authorised professional applications.
Masteron is a widely recognised trade or market name associated with Drostanolone Propionate raw powder. The raw powder offered on this page is not a finished branded medicine.
Dromostanolone Propionate raw powder is an alternative spelling and recognised name for Drostanolone Propionate. Both refer to CAS 521-12-0.
The CAS Registry Number for Drostanolone Propionate raw Powder is 521-12-0.
The molecular formula is C23H36O3.
The molecular weight is approximately 360.53 g/mol.
The AAS Raw Pharma specification describes it as a white or almost white crystalline powder.
The stated minimum purity is 99.7%, subject to the COA or other analytical documentation for the supplied batch.
Batch-specific documentation may be available on request. Customers should confirm the exact COA, SDS, or specification provided with the relevant lot.
AAS Raw Pharma lists it as a pharmaceutical raw-material grade. Customers should review the applicable specification and supporting documents to determine whether it satisfies their requirements. This description does not mean the powder is a finished or approved medicine.
No sterility claim should be assumed. Unless a batch has been produced, tested, and released under a documented sterile specification, treat it as non-sterile raw material.
No. Raw powder is not a finished injectable preparation and must not be injected or directly administered.
No. It is not intended for direct ingestion, injection, self-administration, bodybuilding, or veterinary use.
No. Dosing and steroid-cycle instructions are inappropriate for a bulk raw material. Medical guidance must come from a licensed healthcare professional using an authorised finished product.
They contain different ester groups and are distinct chemical substances with different CAS numbers, formulas, and molecular weights. They are not interchangeable raw materials.
Samples may be available for qualified customers, depending on inventory, intended use, destination regulations, verification, and commercial terms.
Bulk enquiries may be assessed according to quantity, stock, production capacity, documentation, destination, and legal requirements.
Available options may include sealed foil bags, protective containers, or approved bulk packaging. The final format depends on quantity and transport requirements.
Keep it tightly sealed, protected from light, and secured against unauthorised access. Follow the exact temperature and storage conditions stated on the product label and batch documentation.
International shipment may be possible where the transaction and transport are lawful. The buyer must verify import, possession, licensing, carrier, and customs requirements.
No. Customs clearance is controlled by the relevant authorities. The buyer remains responsible for permits, declarations, duties, taxes, and destination-country compliance.
Provide the quantity, destination, organisation details, intended lawful use, preferred packaging, and required documentation. AAS Raw Pharma can then evaluate the enquiry.
| Specification | Product information |
|---|---|
| Product name | Drostanolone Propionate Raw Powder |
| Alternative name | Dromostanolone Propionate |
| Common market name | Masteron, Masteron Propionate |
| Chemical name | 17-beta-hydroxy-2-alpha-methyl-5-alpha-androstan-3-one propionate |
| CAS number | 521-12-0 |
| EINECS number | 208-303-1 |
| UNII | X20UZ57G4O |
| Molecular formula | C23H36O3 |
| Molecular weight | 360.53 g/mol |
| Stated purity | 99.7% minimum, subject to batch documentation |
| Appearance | White or almost white crystalline powder |
| Physical form | Crystalline solid |
| Listed grade | Pharmaceutical raw-material grade |
| Storage | Sealed, protected from light, and stored according to batch documentation |
| Packaging | Sealed foil bag, rigid protective container, or approved bulk packaging |
| Documentation | Batch-specific COA and technical documents where available |
| Intended users | Qualified laboratories, institutions, and authorised manufacturers |
| Direct human use | Not permitted; this is not a finished product |
